Eli Lilly has raised its revenue guidance for 2024 by $3 billion, after reporting strong growth for tirzepatide in diabetes and obesity, fuelled by the end of supply constraints for starting doses.

People walk past the Nasdaq market site as U.S. stock markets opened Tuesday following Monday’s broad sell-off in New York City, U.S., March 11, 2025. REUTERS/Mike Segar/File photo ...